Parshottam Koradia

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Akash Khobragade, Suresh Bhate, Vijendra Ramaiah et al. · The Lancet · 2022 · 248 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

Anuja Pandit, Nirav Bhalani, Bharat Bhushan et al. · International Journal of Infectious Diseases · 2021 · 65 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +15

Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study

Parshottam Koradia, Shital Kapadia, Yamini Trivedi et al. · Expert Review of Anti-infective Therapy · 2019 · 59 citations · Full text

Medicine, Pharmacotherapy, Urology +15

Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)

Dhananjai Agrawal, Deepak Varade, Hardik Shah et al. · American Journal of Nephrology · 2022 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

Shashi Bhushan B L, Sunil Wanve, Parshottam Koradia et al. · International Journal of Infectious Diseases · 2021 · 28 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15